Recent Press Releases

Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition

Enters definitive agreement to acquire Ikaria, Inc. for $2.3 billion from a group of investors led by Madison Dearborn Partners Transaction expected to be accretive to Mallinckrodt's fiscal...

Actavis Confirms District Court Ruling In Atelvia® Patent Litigation

DUBLIN, March 4, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey has found that United States Patent Nos. 7,645,459...

Lilly and IU School of Medicine Partner on Rotation Program for Medical Students

INDIANAPOLIS, March 4, 2015 /PRNewswire/ -- Students from Indiana University School

AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise

- Adds Imbruvica® a first in class BTK inhibitor approved in multiple indications for blood cancers. - Extensive clinical program with over 50 studies ongoing evaluating Imbruvica® as a...

FDA expands approved use of Opdivo to treat lung cancer

The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression...

Genentech response to Novation survey

Genentech's goal is and always will be to get people the medicines they need. We continue to believe the specialty distribution model is the best way for us to ensure patients receive our infused...

Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke

Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of...

Provides 2015 Adjusted Diluted EPS Guidance Range of $4.00 to $4.30, Representing Year-Over-Year Growth of 17%, or 21% on a Constant Currency Basis

Anticipates 2015 Revenues of $9.6 billion to $10.1 billion, Representing Year-Over-Year Growth of 28%, or 33% on a Constant Currency Basis POTTERS BAR, England and PITTSBURGH, March 2, 2015...

Survey Results: Genentech's Decision to Change Distribution of Critical Cancer Drugs Raises Costs, Reduces Availability

IRVING, Texas--(BUSINESS WIRE)--A national survey of pharmacy professionals released today by Novation, the leading health care services company, found that a move to specialty drug distribution of...

Roche Annual General Meeting 2015

Shareholders approve all proposals by the Board of Directors Richard P. Lifton and Bernard Poussot elected as new Board members 28th consecutive dividend increase Roche (SIX: RO, ROG; OTCQX:...

Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit

Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy

Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business

POTTERS BAR, England and PITTSBURGH, Feb. 27, 2015 /PRNewswire/ -- Mylan N.V. and Mylan Inc. (Nasdaq: MYL) today announced the successful completion of the acquisition of Abbott Laboratories'...

Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

Study Met Primary Endpoint of Progression-Free Survival Patients Receiving Kyprolis Lived Twice as Long Without Disease Progression THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March...

Endo Reports Fourth Quarter And Full Year 2014 Financial Results

DUBLIN, March 2, 2015 /PRNewswire/ -- Full year 2014 adjusted diluted EPS exceeds top end of guidance by $0.06 Total quarterly revenues of $800 million brings full year revenues to top end of...

Novartis announces completion of transactions with GSK

Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus...

GSK completes major three-part transaction with Novartis

£4 billion to be returned to shareholders Q1 Results & Investor Meeting to be held on 6 May 2015 GlaxoSmithKline plc (LSE/NYSE: GSK) announces that its three-part transaction with Novartis...

Novo Nordisk receives Health Canada approval for Saxenda (liraglutide) for the treatment of chronic weight management

MISSISSAUGA, ON, Feb. 26, 2015 /CNW/ - Novo Nordisk today announced that Health Canada has approved the New Drug Submission for Saxenda® (liraglutide), the first once-daily human glucagon-like...

Bayer Receives EU Approval for EYLEA for the Treatment of Retinal Vein Occlusion

BERLIN, Germany I February 26, 2015 I Bayer HealthCare announced today that EYLEA® (aflibercept solution for injection into the eye) has been approved by the European Commission for the...

Toujeo® Receives Positive Opinion from the European Regulatory Authorities

Paris, France - February 27, 2015 - Sanofi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion...